Merck (MRK)

Re: Merck (MRK)

Postby winston » Tue May 22, 2018 9:53 am

not vested

Blue-Chip Stocks That Aren’t Really Blue Chips: Merck

Merck & Co., Inc. (NYSE:MRK) is in a position that is somewhat similar to JNJ. One of the reasons I prefer JNJ over MRK is that the former is a big seller of consumer products as well as being a pharmaceutical company.

Merck is only a pharmaceutical company. Again, not to complain about more than $5 billion in annual profit, but I don’t like the fact that free cash flow has fallen to $4.6 billion from almost $12 billion a couple of years ago.

Not only that, this so-called blue-chip stock was barely able to cover the dividend from free cash flow last year.

Merch is trading at almost 30 times earnings against annualized earnings growth of less than 7%.

Source: Investor Place
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Merck (MRK)

Postby winston » Tue Mar 26, 2019 9:52 pm

THE BULLISH TREND CONTINUES FOR HEALTH CARE STOCKS

Today, we're checking in on the bull market in health care...

Our colleague Dr. David Eifrig believes the health care industry is benefiting from a massive tailwind. According to the Population Reference Bureau, the number of Americans older than 65 will more than double by 2060. That means more people will need medical care. And today's company is a major supplier of drugs and medicine...

Merck (MRK) is a $210 billion pharmaceutical giant. The company makes lifesaving drugs like Januvia, Keytruda, and Zetia... all of which help fight common conditions in seniors (diabetes, cancer, and high cholesterol, respectively).

Merck also makes vaccines for diseases like measles, mumps, and shingles. Providing medical treatment is big business these days... In 2018, Merck reported sales of more than $42 billion, the highest since 2013.

As you can see in today's chart, MRK shares are trending higher. The stock is up more than 50% over the past year, and it recently hit a new multiyear high. As the bull market in health care rages on, MRK should have more gains in its future...

Source: Daily Wealth
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Merck (MRK)

Postby winston » Wed Aug 14, 2019 2:35 pm

not vested

Merck (MRK)

The steadfastness of the healthcare sector makes it a prime place to find plenty of blue-chip stocks. And one of the best could be pharmaceutical giant Merck (NYSE:MRK).

For starters, MRK features a wide portfolio of current and former blockbuster drugs, vaccines and other therapies.

This huge portfolio continues to drive profits and cash flows at the giant. But MRK isn’t resting on its laurels.

A few years ago, Merck made the shift into newer biotech and advanced cancer-fighting medications. That has turned out to be the right move.

MRK’s Keytruda has quickly become the go-to medicine for a variety of lung cancers and sales going through the roof. Last quarter alone, the company reported more than $2.2 billion in Keytruda sales.

That double-digit growth has allowed Merck to up its total forecast and guidance for the entire year.

The growth of Keytruda could continue. Merck has begun several trials looking to use the drug in other indications. This could provide even more cash flowing Merck’s way.

Considering the growth of its cancer portfolio and the rest of its steady drug options, Merck is looking like a great buy for the long haul.

In the end, MRK’s 2.5% yield and continued growth make it a powerful blue-chip stock for any investor.

Source: Investor Place
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Merck (MRK)

Postby winston » Mon Aug 26, 2019 9:30 am

not vested

RECOMMENDATION

We have a TECHNICAL BUY rating for MRK. MRK is currently trading at a P/E ratio of 17.9,
which is below its historical average.

We believe the stock price of MRK is attractive given its potential upside from the strong organic growth led by Keytruda.

Source: Phillips

https://internetfileserver.phillip.com. ... 082019.pdf
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Merck (MRK)

Postby winston » Tue Dec 10, 2019 9:15 pm

not vested

THIS DRUG GIANT'S FLAGSHIP TREATMENT WILL LEAD SALES IN 2023

Today, we're checking in on a company thriving in the bull market in health care...

As Baby Boomers continue to age, they'll need more medical care. That means more check-ups, prescriptions, vaccines, and more. Today's company is profiting from this trend...

Merck (MRK) is a $225 billion drugmaker. It produces lifesaving drugs like Januvia and Janumet (diabetes), Keytruda (cancer), and more.

With its expansive portfolio, Merck is able to treat many conditions, including those common in seniors. And that's great for sales...

In the most recent quarter, Merck reported sales of $12.4 billion, up 15% from the same quarter last year. And that sales growth should only continue...

Research firm GlobalData predicts Keytruda will be the world's top-selling drug by 2023.

As you can see in today's chart, shares have been in a steady uptrend. The stock is up roughly 45% over the past year and a half. As long as patients rely on Merck's lifesaving drugs, these gains should continue...

Source: Daily Wealth
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Merck (MRK)

Postby winston » Thu Feb 20, 2020 1:13 pm

not vested

Merck & Co., Inc. (MRK)

Throughout the last 125 years, healthcare name Merck & Co. has become one of the major players in the space. While shares have slipped in the previous six months, Simons’ fund just pulled the trigger.

According to the fund’s 13F filing, Renaissance bought 1,625,830 shares in the fourth quarter, reflecting a 41% increase. As its MRK stake now lands at 5,673,243, the total position is valued at almost $516 million.

After its recent earnings release, analysts are also optimistic when it comes to Merck’s long-term growth prospects. In terms of non-GAAP EPS, the figure came in 1 cent ahead of the consensus at $1.16.

Sales, however, missed the mark at $11.9 billion, which was $85 million below the Street’s prediction. MRK also revealed that it would be spinning off the women’s health, legacy brands and biosimilars into a NewCo.

Weighing in on the company for Cantor Fitzgerald, Louise Chen writes that even though the print has caused investors to worry about slowing Keytruda sales, new data readouts for drugs that compete with MRK’s products and NewCo’s impact on EBITDA, the company is on track.

The analyst highlights the fact that Keytruda, animal health, human health vaccines and overall worldwide sales all gained during the quarter. Not to mention through 2024, Merck expects solid revenue growth, which should accelerate thanks to the spin-off.

“As a result of the incremental growth that NewCo is expected to achieve, combined with the benefit of ongoing operating efficiencies at MRK enabled by the spinoff, the company expects MRK and NewCo to realize higher combined non-GAAP EPS within 12-24 months post-spinoff,” Chen argued.

Bearing this in mind, the analyst stayed with the bulls, reiterating an Overweight rating. At $107, the price target implies that a 30% twelve-month climb could be in the cards.

Meanwhile, Guggenheim’s Seamus Fernandez thinks the spin-off is the primary takeaway. “More important is today's news of the spin of the women's health, legacy brands and biosimilars into a NewCo, which we view as financially creative and potentially compelling, but further levers MRK to Keytruda.

The strategic plan highlights MRK's conviction in its long-term growth prospects and, financially, we believe the decision makes sense long-term,” he explained. To this end, the five-star analyst left his Buy call and $105 price target as is. (To watch Fernandez’s track record, click here)

Looking at the consensus breakdown, 6 Buys and 1 Hold add up to a Strong Buy consensus rating. With a $99.38 average price target, the upside potential is 21%.

Source: TipRanks
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Merck (MRK)

Postby winston » Thu Feb 04, 2021 4:31 pm

Exclusive: Merck anti-baldness drug Propecia has long trail of suicide reports, records show

Source: Reuters

https://www.reuters.com/article/BigStor ... SKBN2A32XU
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Merck (MRK)

Postby winston » Mon Nov 29, 2021 9:05 am

not vested

Molnupiravir

An anti-Covid pill developed by Merck has proved effective in treating the disease, the US Food and Drug Administration (FDA) said Friday (Nov 26) in a much-awaited preliminary report.

But the report, from an FDA advisory panel, cautioned that pregnant women should not use the drug, known as molnupiravir, saying the potential benefits do not outweigh the risks for those patients.

The report is meant to provide guidance to an FDA experts panel convening Tuesday (Nov 30) to consider whether to authorise emergency use of molnupiravir.

Approval, analysts say, would represent a major step forward in the battle against the global pandemic, handing healthcare professionals a powerful new tool to help those infected.

Source: Phillips
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Merck (MRK)

Postby winston » Mon Nov 29, 2021 9:07 am

not vested

Recommended: Technical BUY

Merck & Co (US: MRK) Technical price action shows a bullish rebound despite a break below the diamond top pattern

Buy spot: 79.16 Stop loss: 75.00
Take profit 1: 90.00 Take profit 2: 96.41

Source: Phillips

https://www.stocksbnb.com/tech-pulse/te ... -co-inc-2/
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Previous

Return to L to R

Who is online

Users browsing this forum: No registered users and 6 guests

cron